In brief
The episode argues that the U.S. entered the Covid winter of 2021 still unprepared in ways that were foreseeable. Helen Branswell says models suggest the Delta wave could ebb after Thanksgiving, but only if no new variant appears. Scott Gottlieb argues that pandemic planning focused on flu, neglected testing, and left a CDC that lost public trust.
The main tension is between short-term hope and long-term fragility. Models are cautiously optimistic, yet booster rules are messy, global vaccine supply is thin, and public confidence in health agencies has eroded. A lighter thread follows Biogen's Aduhelm, which approval did not turn into patients: only about 100 had been treated, held back by skepticism, logistics and price.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Biogen's Aduhelm was approved in June 2021, and by September 11, 2021 about 100 people had received it commercially outside clinical trials.
“Aduhelm was approved in June. And as of September 11th, about 100 people have received the drug on a commercial basis outside of a clinical trial.”
0:08:13 · Host · Aduhelm launch · 2021
Biogen priced Aduhelm at an average of $56,000 a year, which Damian Garde said added to skepticism about the drug.
“the really massive thing is that Biogen chose to charge an average of $56 ,000 a year for this medicine, which added to the skepticism over its efficacy”
0:09:12 · Host · Aduhelm price · 2021
Aduhelm is an infused therapy given once a month, and Damian Garde said the infrastructure to deliver it was not necessarily in place.
“it's an infused therapy and it's infused once a month is not necessarily in place for people to even get on it”
0:08:44 · Host · Aduhelm logistics · 2021
The FDA authorized Pfizer's Covid booster for people six months past their primary series who are 65 or older or at high risk of severe Covid.
“The FDA has authorized Pfizer's booster for people six months out from their primary vaccination, people 65 and older, people who are at high risk of severe outcomes of COVID”
0:04:54 · Meg Terrell · Booster authorization · 2021
Acting FDA Commissioner Janet Woodcock said the high-exposure group for Pfizer boosters includes teachers, daycare workers, grocery workers, and people in prisons and homeless shelters.
“Dr. Janet Woodcock, the acting FDA commissioner, specified in the FDA's release that includes folks like teachers, daycare workers, grocery store workers, and people who are in prisons and homeless shelters.”
0:04:54 · Meg Terrell · Booster eligibility · 2021
Meg Terrell described the booster approval path as FDA advisers, then the FDA, then the CDC's advisory committee, then CDC director sign-off.
“the FDA has to decide and the CDC's advisory group meets and then the CDC director signs off on it”
0:04:33 · Meg Terrell · Approval process · 2021
Johnson & Johnson released a long press release combining data from several studies, including a second shot given two months later.
“Johnson & Johnson putting like four studies worth of information into one very long press release where they talked about their second shot two months later.”
0:05:45 · Meg Terrell · J&J data · 2021
A study of remdesivir in non-hospitalized patients, given as three days of IV treatment, suggested it could keep people out of the hospital, as monoclonal antibodies can.
“You have to get three days of IV treatment. It suggested that can keep you out of the hospital as potentially as well as monoclonal antibodies.”
0:06:14 · Meg Terrell · Remdesivir · 2021
Adam Feuerstein said Merck, Pfizer and another company were developing oral Covid antivirals, and that remdesivir's effect gave reason for optimism.
“oral antivirals that we've spoken about from Merck, a company called Atia Pharmaceuticals, and a company called Pfizer that are now in development”
0:06:44 · Host · Oral antivirals · 2021
The Biden administration wanted boosters for everyone, but the FDA's advisory committee VRPAC said the evidence did not support that.
“the Biden administration had wanted to offer boosters to everyone and, uh, the FDA's advisory committee, VRPAC, had said, no, we don't think the evidence supports that.”
0:14:45 · Helen Branswell · Booster debate · 2021
The booster emergency use authorization covered only Pfizer's vaccine, which just under half of vaccinated Americans had received.
“this EUA only covers the Pfizer vaccine. And just under half of the American population that's been vaccinated got the Pfizer vaccine.”
0:16:07 · Helen Branswell · Booster coverage · 2021
Helen Branswell said Covid vaccine priority groups ran on an honor system, with no requirement to prove a health condition.
“there was never any requirement that you prove that you were a diabetic or that you had hypertension”
0:17:25 · Helen Branswell · Vaccine eligibility · 2021
STAT polling found that vaccinated Trump voters were much less likely than vaccinated Biden voters to plan to get a booster.
“A lot fewer vaccinated Trump voters plan to get a booster than vaccinated Biden voters.”
0:18:34 · Meg Terrell · Booster polling · 2021
Helen Branswell said India was expected to supply much of the developing world's vaccine but was swamped by the Delta variant, which disrupted exports.
“India was going to be the producer for much of the developing world. And then India got swamped by the Delta virus”
0:22:58 · Helen Branswell · Vaccine supply · 2021
Former CDC director Tom Frieden criticized Moderna and Pfizer for not sharing expertise and patents to expand vaccine manufacturing abroad.
“he also is really taking aim at the companies, Moderna and Pfizer in particular, for not sharing their expertise and their patents”
0:22:01 · Meg Terrell · Vaccine equity · 2021
Scott Gottlieb sits on the boards of Pfizer and Illumina, is a senior fellow at the American Enterprise Institute, and is a CNBC contributor.
“which also includes board member of Pfizer and Illumina, senior fellow at the American Enterprise Institute and CNBC contributor.”
0:25:35 · Host · Gottlieb roles · 2021
Scott Gottlieb said U.S. pandemic tabletop exercises, including Crimson Contagion just before Covid, were built around an influenza pandemic.
“all of the tabletop exercises that we had done, and I had been a part of some of those, prepped for a potential pandemic with an influenza, including crimson contagion, which happened just before COVID ended up striking.”
0:26:38 · Host · Pandemic preparedness · 2019
Scott Gottlieb said the U.S. stockpile held respirators that did not work and out-of-date masks.
“Respirators that we had stockpiled didn't work. The masks were out of date.”
0:27:08 · Host · Strategic stockpile · 2020
Scott Gottlieb said diagnostic testing was not a major part of pandemic exercises like Crimson Contagion, because flu planning relied on existing doctor's-office flu tests.
“if you look back at the pandemic tabletop exercises like crimson contagion, diagnostic testing wasn't a big part of those exercises.”
0:27:08 · Host · Testing gap · 2019
The host summarized Gottlieb's book as saying the CDC botched its first SARS-CoV-2 test and failed to plan for widespread testing.
“they botched the development of the first SARS-CoV-2 test. They failed to come up with a plan for widespread testing”
0:28:06 · Host · CDC testing · 2020
Scott Gottlieb argued against creating a new agency, like the Department of Homeland Security created after 9/11, for pandemic planning, preferring to reform the CDC.
“we should be creating a new agency or creating a new Department of Homeland Security that's focused on pandemic planning like we did after 9-11.”
0:29:02 · Host · CDC reform · 2021